trials – Talk Bio

Corsera Health Launches with $50M Funding for Preventive Cardiovascular RNAi Program Advancing to Clinic

3 weeks ago talkbio0Tagged Ambulatory Care Facilities, Cardiovascular Diseases, Corsera Health, Funding, Preventive Health Programs, RNAi medicine, trials

Corsera Health; cardiovascular disease; RNAi medicine; preventive program; clinic trials; funding; $50M

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

4 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

6 months ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)

6 months ago talkbio0Tagged Artificial Intelligence, Clinical Trials, Data Integration, Data Quality, DCT gene, decentralized, Diversity, Preventive monitoring, regulatory guidance, Remote, risk-based oversight, trials

decentralized clinical trials; DCT; data quality; patient diversity; remote monitoring; AI in trials; data integration; risk-based oversight; clinical trial data; regulatory guidance

FDA Advisory Panel Rejects GSK’s Blenrep in New Combinations Over Safety, Efficacy Concerns

7 months ago talkbio0Tagged Advisory Panel, Blenrep, concerns, DREAMM, Drug Approval, Multiple Myeloma, Ocular Toxicity, Refractory Plasma Cell Myeloma, Relapsing course, Safety, SmithKline Beecham, trials, United States Food and Drug Administration

Blenrep; GSK; FDA Advisory Panel; multiple myeloma; ocular toxicity; safety concerns; DREAMM trials; drug approval; relapsed or refractory multiple myeloma

Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials

1 year ago talkbio0Tagged Analog, BOS-580, Clinical Trials, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, metabolic dysfunction-associated steatohepatitis, Nonalcoholic Steatohepatitis, Phase 2, trials

Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials

Medidata Introduces Bundled Solutions for Oncology and Vaccine Trials to Enhance Study Efficiency

1 year ago talkbio0Tagged adaptive trial designs, Bundled, Clinical Trials, Diversity, Efficiency, Endpoints, Medidata, Patient-Centered, Solutions, trials, Vaccines

Medidata, Oncology Trials, Vaccine Trials, Bundled Solutions, Clinical Trial Efficiency, Patient-Centered Endpoints, Adaptive Trial Designs, Trial Diversity